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Abstract: We aimed to describe the clinical features and outcomes of pyogenic spondylodiscitis and to
identify factors associated with an unfavourable clinical outcome (defined as death, permanent
disability, spinal instability or persistent pain). In our tertiary centre, 91 cases were identified
prospectively and a retrospective descriptive analysis of clinical records was performed prior to
binary regression analysis of factors associated with an unfavourable outcome. A median 26 days
elapsed from the onset of symptoms to diagnosis and 51% of patients had neurological impairment
at presentation. A microbiological diagnosis was reached in 81%, with Staphylococcus aureus
most commonly isolated. Treatment involved prolonged hospitalisation (median stay 40.5 days),
long courses of antibiotics (>6 weeks in 98%) and surgery in 42%. While this was successful in
eradicating infection, only 32% of patients had a favourable clinical outcome and six patients (7%) died.
Diabetes mellitus, clinical evidence of neurological impairment at presentation, a longer duration of
symptoms and radiological evidence of spinal cord or cauda equina compression were independent
factors associated with an unfavourable outcome. Our data indicate that spondylodiscitis is associated
with significant morbidity and suggest that adverse outcomes may be predicted to an extent by factors
present at the time of diagnosis.
Keywords: spondylodiscitis; vertebral osteomyelitis; bacterial; antibiotics; outcomes
1. Introduction
Pyogenic spondylodiscitis is defined as a serious infection of the intervertebral disc(s) and/or
adjacent vertebrae, and for the purpose of this article incorporates both vertebral osteomyelitis and
spondylodiscitis [1]. It may occur due to haematogenous seeding during a bacteraemia, direct spread
from an adjacent focus of infection or as a consequence of inoculation during spinal surgery [2].
Although relatively rare, the incidence of spondylodiscitis appears to be increasing (for example in
Japan from 5.3 per 100,000 in 2007 to 7.4 per 100,000 in 2010) presumably due to a combination of
population aging and advances in diagnostic tools [3,4]. However, there is a critical lack of information
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about the natural history and long-term clinical outcomes of spondylodiscitis. Furthermore, individual
patient and disease-related factors that might contribute to clinical outcome are poorly defined.
The diagnosis of pyogenic spondylodiscitis requires a high index of clinical suspicion combined
with early microbiological and radiological investigation (Figure 1). Early diagnosis is important
as spondylodiscitis is often associated with abscess formation in the epidural space and adjacent
soft tissues and muscle. The effects of local inflammation and abscess formation can lead to spinal
cord compression and/or vertebral column instability, resulting in permanent neurological deficits.
Management involves a combination of prolonged antimicrobial therapy and surgical intervention but
is based on a very limited evidence base [1,4].
To address the clinical need for better data on natural history and outcome, we sought to describe
the presentation, management and outcome of pyogenic spondylodiscitis in a tertiary centre for spinal
surgery and infectious diseases.
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2. Materials and Methods
Data were collected as part of routine clinical service evaluation at Newcastle Upon Tyne Hospitals
NHS Trust, a large teaching trust with 1800 beds that manages over 1.72 million patient contacts
per year and is a tertiary referral centre for both Spinal Surgery and Infectious Diseases services.
Cases of bacterial spondylodiscitis between 1 May 2013 and 31 May 2016 were prospectively identified
upon referral for infectious diseases consultation. The inclusion criteria were: adult patients (aged
16 years or over), a radiological diagnosis of pyogenic spondylodiscitis and a bacterial aetiology
confirmed by microbiological culture or a bacterial aetiology not confirmed but thought likely by
the treating infectious diseases team. The exclusion criteria were: children (aged under 16 years),
confirmed tuberculous (n = 2) or fungal (n = 1) spondylodiscitis or the absence of clinical outcome
data (n = 7). Subsequent to the prospective case identification, anonymised details of clinical and
radiological presenting features, microbiological diagnosis, and surgical and antimicrobial treatment
were retrospectively obtained from clinical and laboratory records and recorded using a standardised
proforma and/or directly entered onto a database (Microsoft Excel, Redmond, WA, USA). The degree
of neurological impairment was retrospectively determined using the Frankel grading scale of
neurological injury [5] using data collected at the time of clinical assessment. The Frankel scale
has the following grades differentiated by the residual function below the level of injury: A, complete
loss of motor and sensory function; B, preserved sensation only; C, preserved motor activity of no
practical use to the patient; D, preserved impaired but useful motor function; and E, normal motor and
sensory function. This functional scale has been previously used in studies of spondylodiscitis [6,7].
Outcome data were collected retrospectively using clinical and electronic patient records. Patients were
classified as having a favourable outcome (complete recovery) or an unfavourable outcome, defined as
either death during hospital admission or the presence of physical disability and/or persistent pain at
one year or, if earlier, the point of discharge from follow-up.
Statistical analysis was carried out using GraphPad Prism 6 (GraphPad, La Jolla, CA, USA)
software using t-test for continuous data and Fisher’s exact test for categorical data. Multivariate
binary logistic regression analysis of factors that were significant in univariate analysis was carried out
using Minitab 17 (Minitab Limited, Coventry, UK). Two-tailed α < 0.05 was considered significant.
3. Results
3.1. Baseline Features
We identified 98 patients with pyogenic spondylodiscitis. Full outcome data were available on
91/98 patients. Patients in the cohort had a median age of 61 years (range 17–90 years). Fifty-five (60%)
of these patients were male, which is in keeping with the known male preponderance. A pre-existing
condition causing impaired immunity was present in 31 (34%) patients: 16 had diabetes mellitus,
11 were on various immunosuppressive agents for autoimmune diseases, six had active cancer and one
had a splenectomy (three patients had more than one of these conditions). In addition, 20 (22%) patients
had a history of spinal surgery within the past three years: six infections occurred after decompressive
laminectomy, six after discectomy, five after spinal fixation, one after vertebroplasty, one after insertion
of a spinal stimulator and one after resection of a retroperitoneal sarcoma. Four patients (4%) were
active injecting drug users.
3.2. Clinical Findings
Although the majority of patients with spondylodiscitis reported spinal pain and/or
radiculopathy at presentation, other presenting symptoms were less universal (Figure 2A). Notably,
self-reported or objectively documented fever was absent in 34 (37%) patients. At presentation,
46 patients (51%) had a Frankel grading score of A–D indicating various degrees of impairment
of motor function; of these patients, 31 had a spinal epidural abscess, six had vertebral instability,
five had a prevertebral or paravertebral abscess and in the remaining four spondylodiscitis was
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the only identifiable cause for the neurological impairment, which was presumably secondary to
nerve root impingement. There was considerable variation in the reported duration of symptoms,
but spondylodiscitis generally had a subacute presentation with median symptom duration of 26 days
(range 1–203 days) prior to diagnosis.
The diagnosis of spondylodiscitis was suggested by characteristic features on magnetic resonance
imaging (MRI) of the spine. Spondylodiscitis occurred throughout the spine, with a preponderance for
the lumbar and lumbosacral spine (50 patients, 55%), and more than one disc space was involved in
27 (30%) patients (Figure 2B). Furthermore, 55 (60%) patients had spinal epidural abscess formation
and 32 (35%) had radiological evidence of spinal cord/cauda equina compression at presentation
(Figure 2C).
The most common source of infection was haematogenous spread (48 patients, 53%).
Twenty patients (22%) had an infection following spinal surgery while seven patients (8%) had spread
from an identified contiguous source of infection (e.g., intra-abdominal infection). The underlying
source of infection was not identified in 16 patients (17%) (Figure 2D).
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presence/absence of important symptoms in patients presenting with discitis; (B) the distribution of
spondylodiscitis between different anatomical regions; (C) the number of patients with complications of
spondylodiscitis identified on MRI imaging at presentation; and (D) the underlying source of infection
in patients with spondylodiscitis.
3.3. Microbiology
A microbiological aetiology was confirmed in 74 (81%) patients, 62 of whom had a single organism
identified and the remaining 12 had multiple organisms identified. Bacteria were isolated from
blood cultures in 40 patients (51% of the 78 patients from whom blood cultures were obtained),
image-guided biopsy samples in 21 patients (72% of 29 patients) and surgical samples in 25 patients
(66% of 38 patients). Gram-positive bacteria were most commonly cultured, followed by Gram-negative
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bacteria and anaerobes. The most commonly identified bacterial pathogens were Staphylococcus aureus
(35 patients, 38%), coagulase negative Staphylococci (11 patients, 12%) and Escherichia coli (11 patients,
12%) (Table 1). Although antimicrobial resistance data are not included here, this was not a major
problem in our cohort of patients, as illustrated by the finding that only 1/35 (3%) of patients in which
S. aureus was isolated had a methicillin-resistant strain. As expected, there was a significant association
between the isolation of coagulase negative Staphylococci and spondylodiscitis post-spinal surgery
(5/20 patients with post-surgical infection vs. 6/69 other patients, p = 0.049). There were no other
associations between baseline factors (e.g., surgical infection, immunocompromise, diabetes, etc.) and
microbiological diagnosis.










All 58 46 12
Staphylococcus aureus 35 33 2
Coagulase negative
Staphylococci 11 6 5
Enterococcus faecalis 3 1 2
Streptococcus pneumoniae 3 3 0
Viridans group Streptococci 3 1 2
Group B Streptococci 2 2 0
Group C/G Streptococci 1 0 1
Gram
negative
All 17 13 4
Escherichia coli 11 10 1
Klebsiella pneumoniae 2 1 1
Others 4 2 2
Anaerobes
All 9 3 6
Proprionibacterium acnes 4 2 2
Others 5 1 4
The causative organisms isolated by microbiological culture from blood, biopsy and surgical samples are listed with
subgrouping depending on whether they were isolated alone or with other organisms.
3.4. Treatment
Surgical intervention occurred in 38 patients (42%), 13 of whom required more than one procedure
(Figure 3A). A decompressive laminectomy was the most common surgical procedure, while 16 patients
(18%) required spinal fixation or fusion (either at the time of presentation (14/16) or following
antimicrobial treatment (2/16)). Epidural abscess was drained surgically in 28 (51%) of the 55 patients
with radiological evidence of epidural abscess (Figure 3B).
In general, patients were treated with systemic antibiotic therapy for a minimum of 6 weeks
(89 patients, 98%). In most cases, this consisted of an initial intravenous antibiotic-containing regimen
(88 patients, 97%) for a minimum of 4 weeks (80 of these 88 patients, 91%) followed by an additional
oral regimen (70 of these 88 patients, 80%). Combination therapy with two antibiotics was most
common (Figure 4A). Beyond these broad principles, there was wide variation in the actual antibiotic
regimens used for both intravenous and oral therapy and the total duration of treatment (Figure 4B).
The same antibiotic regimen was used throughout treatment in the minority of patients (seven patients,
8%), with most having two or three different regimens (Figure 4C).
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3.5. Clinical Outcomes
Spondylodiscitis was generally associated with a long duration of hospital admission with a
median stay of 40.5 days (range 6–207). The majority of patients had an improvement in symptoms
and motor/sensory function after treatment, as reflected by changes in the Frankel grading score
(Figure 5A). However, in addition to a fatal outcome in six (7%) patients, there was significant
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long-term morbidity in the majority with only 29 (32%) patients experiencing a complete recovery.
In the other patients, 28 (31%) had significant ongoing spinal pain or radiculopathy requiring regular
analgesia, 24 (26%) had persistent neurological impairment and four (4%) had vertebral instability
requiring further surgical or orthotic intervention following treatment of the infection (Figure 5B).
Subsequent analysis revealed that the following factors at the time of diagnosis of spondylodiscitis were
significantly predictive of unfavourable outcome: diabetes mellitus, clinical evidence of neurological
impairment at presentation (Frankel grading score A–D), a longer duration of symptoms prior
to presentation and radiological findings suggestive of spinal cord/cauda equina compression
(Tables 2 and 3).Med. Sci. 2018, 6, x FOR PEER REVIEW  7 of 11 
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Age (median (range)) 62.5 (17–91) 59 (17–90) 64 (35–91) 0.121
Diabetes mellitus (n (%)) 16 (18) 1 (3) 15 (24) 0.017 *
Immune compromise (n (%)) 18 (20) 3 (10) 15 (24) 0.162
Post-surgical (n (%)) 16 (18) 5 (17) 11 (18) >0.99
Presenting features
Sepsis (n (%)) 22 (24) 7 (24) 15 (24) >0.99
Frankel grading scale A–D (n (%)) 46 (51) 5 (17) 39 (63) <0.001 *
Duration of symptoms (median days (range)) 36 (1–203) 27 (1–71) 41 (2–203) 0.049 *
C-reactive protein (median mg/L (range)) 170 (4–508) 143 (15–395) 181 (4–508) 0.157
White blood cell count (median × 109 (range)) 13.1 (6.0–33.7) 12.2 (6.6–24.3) 13.6 (6.0–33.7) 0.18
Endocarditis 4 (4) 1 (3) 3 (5) >0.99
Radiological features
Epidural abscess (n (%)) 55 (60) 16 (55) 39 (63) 0.467
Multiple level discitis (n (%)) 27 (30) 6 (20) 21 (34) 0.228
Cord/cauda equina compression (n (%)) 32 (35) 5 (17.2) 27 (44) 0.018 *
Vertebral instability (n (%)) 12 (13) 2 (7) 10 (16) 0.325
Microbiological diagnosis
Bacteraemia (n (%)) 47 (52) 18 (62) 29 (47) 0.187
Staphylococcus aureus (n (%)) 35 (39) 10 (35) 25 (40) 0.649
1 Unfavourabl outcome was defined as death, long-term physical disability or persistent pain requiring regular
analgesia. 2 The significance of the differences between the groups with favourable and unfavourable outcomes
was analysed using indepe dent t-tests for continuous variables and Fisher’s exact testing for categorical variables.
* indicates p < 0.05.
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Table 3. Binary logistic regression of factors predicting an unfavourable outcome from spondylodiscitis.
Risk Factor Odds Ratio 95% Confidence Interval p-Value
Diabetes mellitus 5.88 1.40–24.68 0.008
Frankel grading scale A–D 4.52 1.25–16.39 0.019
Duration of symptoms 1.02 1.00–1.04 0.019
Spinal cord/cauda equina compression 6.49 1.42–29.70 0.009
4. Discussion
This study provides a comprehensive assessment of the presentation, diagnosis, management
and outcomes of 91 prospectively-identified adults treated for bacterial spondylodiscitis over
three years in a tertiary referral centre. In keeping with previous studies, we have shown that
spondylodiscitis is more common with increasing age and male gender and that the presenting
features are highly variable [2,8–12]. In this “real world” dataset, a combination of blood and biopsy
culture enabled a microbiological diagnosis to be reached in the majority of patients. Indeed, half of
patients had a positive blood culture, reinforcing the importance of this simple investigation in
patients with suspected spondylodiscitis. S. aureus was the most common pathogen, consistent
with existing reports [2,11]. Importantly, our data demonstrate that, despite prolonged and
microbiologically-targeted antibiotic therapy, and a reasonably high rate of surgical intervention,
spondylodiscitis was associated with significant adverse outcomes including prolonged hospital stay,
persistent pain, long-term disability and death, with less than one third of patients making a complete
recovery. As we identified no evidence of infection relapse, these sequelae are most likely to relate to
the damage done during the initial illness.
Few studies report on patient-related factors which are associated with poor outcome in
spondylodiscitis. We found that an unfavourable outcome was predicted by the presence of the
following risk factors at the point of diagnosis: diabetes mellitus, longer interval between symptom
onset and diagnosis, neurological impairment at diagnosis (Frankel grade A–D) and radiological
evidence of spinal cord or cauda equina compression. In agreement with our findings, a prospective
study of 81 patients revealed that the presence of a neurological deficit at diagnosis and delay in
presentation of greater than 60 days was significantly associated with persistence of neurological
deficit or relapse of infection [9]. Similarly, in a retrospective analysis of 253 patients, death or
incomplete recovery from spondylodiscitis was associated with neurological compromise at diagnosis,
delayed diagnosis and nosocomial acquisition of infection [10]. Other studies have focused on
specific outcomes, for example severe neurological dysfunction or death. A large retrospective study
which specifically addressed risk factors for mortality (but not morbidity) identified increased age,
diabetes mellitus, cirrhosis, malignancy, haemodialysis use and concomitant infective endocarditis as
independent factors [3]. Another retrospective study of 62 patients found that an adverse neurological
outcome was significantly more likely in those patients with concomitant spondylodiscitis and infective
endocarditis. It should be noted that in our study very few patients were diagnosed with concomitant
endocarditis, although only 55 patients (60%) had indications for an echocardiogram [12] More
recently, a study incorporating patients recruited to an open-label randomised controlled trial (RCT),
discussed further below, examined factors that were associated with severe neurological deficit at
baseline (but not outcome): these factors were cervical or thoracic spinal involvement, S. aureus
infection and C-reactive protein > 150 mg/L [13].
Collectively, the outcome from spondylodiscitis appears to be largely governed by factors present
at the time of diagnosis. For several reasons, spondylodiscitis is a difficult diagnosis to make without
a high index of suspicion, considering its rarity compared to more common causes of back pain.
Therefore, diagnostic delay is a common theme in the literature [4,10,14]. Timely diagnosis appears to
be vital to prevent the onset of neurological deficit and/or spinal instability [1] and could be aided by
increased awareness of the diagnosis amongst primary care and general physicians as well as the wider
public, and potentially by expanding access to spinal imaging. Reducing diagnostic delay is critical,
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since any advances in treatment are unlikely to yield significant benefits unless allied to improvements
in diagnosis. While the presence of factors associated with a worse outcome cannot necessarily
be mitigated, our study highlights that there might be a potential role for individualised therapy
(e.g., intensified antibiotics or adjunctive therapy) to improve outcome in patients with pre-existing
diabetes and baseline neurological impairment.
While there was considerable heterogeneity in terms of antimicrobial therapy used in our dataset,
the majority of patients received a minimum duration of 6 weeks of therapy, generally involving
combination antibiotic therapy, with an initial intravenous antibiotic-containing regimen followed by
an additional oral antibiotic regimen. This approach is in accordance with that reported elsewhere
and international consensus guidelines suggesting that a minimum of 6 weeks of antibiotic therapy is
required to treat spondylodiscitis [1,15]. However, such guidelines are predominantly based on expert
opinion and the underlying evidence is of poor quality [11,16].
Thus, the optimal duration of antibiotic therapy for spondylodiscitis remains uncertain. The best
evidence available is from an open label non-inferiority RCT of 359 patients which showed no difference
in clinical cure or adverse events with 6 weeks compared to 12 weeks of antibiotic therapy [17]. This is
consistent with a previous retrospective study that found no difference in the risk of mortality or relapse
in 36 patients treated for less than 6 weeks compared to 84 treated for longer [18], although clearly
allocation bias cannot be excluded in this study design. There is very limited evidence to determine
whether intravenous or high-bioavailability oral therapy is superior, although the intravenous route
may be necessary in certain specific scenarios (e.g., the absence of an effective oral option or inability
to tolerate oral antibiotics) [16]. While the previously mentioned randomised controlled trial was
not designed to assess this, 52% of those enrolled received less than 14 days intravenous therapy
and there was no increase in treatment failure in those having intravenous therapy for less than
7 days [17]. However, caution is needed when interpreting such post-hoc analyses. A Cochrane
review of antibiotic therapy for osteomyelitis (predominantly post-traumatic osteomyelitis of the
lower limb) concluded that the route of administration of antibiotics does not appear to alter the
effectiveness of treatment [16], although the quality of studies included was low and it is not clear
that these data can be extrapolated to spondylodiscitis. Finally, while many physicians routinely
prescribe combination antibiotic therapy, the efficacy of this approach has not been formally assessed
in spondylodiscitis. The observation that combination therapy with rifampicin is associated with
better outcomes in osteomyelitis associated with prosthetic material may be relevant to at least a
subset of patients [4,19]. Collectively, the uncertainties summarised above point to the need for
randomised controlled trials to determine the optimal antibiotic management of spondylodiscitis.
For obvious reasons, when considering patient allocation to these studies it will be important to ensure
that the baseline risk factors we have identified are equivalently distributed between intervention and
control groups.
Another area of some uncertainty concerns the role for surgical intervention in the treatment of
spondylodiscitis. Surgery typically involves decompression of the spinal cord and debridement of
infected tissues and/or drainage of abscesses [11]. Indications include the presence of neurological
injury/spinal cord compression, vertebral instability, failure of medical therapy and epidural or
paraspinal abscesses [3,4]. A retrospective study of 90 patients in Taiwan found that the 43 patients
having early surgical intervention had a shorter hospital stay and reduced spinal deformity, pain and
disability compared to those treated conservatively with antibiotics alone [20]. However, conservative
management is increasingly practiced, even in selected patients with spinal epidural abscess [8,21,22],
and this was also the case in our cohort. To some extent, this may be due to concerns about implanting
spinal metalwork into an area of active infection. This concern was not supported by two recent small
retrospective studies that did not demonstrate an increased risk of infection relapse [23,24], although
clearly more data are needed.
We acknowledge some limitations of our study. Whilst cases were identified prospectively,
outcome data were collected and analysed retrospectively and therefore may be subject to bias.
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Our study population represents patients who were managed jointly by infectious diseases and
spinal surgical services at a single institution and might reflect the more severe end of the disease
spectrum. Whether our findings (for example, the low rate of infection relapse) would be generalizable
to patients managed without infectious diseases input remains unclear. Furthermore, although this
is the largest UK cohort and the sample size compares well to previous studies, the sample size may
have limited our power to identify additional treatment-related factors important to clinical outcome,
which will be better assessed through a large multi-centre observational study. Finally, it can also be
argued that post-surgical infections may represent a distinct pathogenic process to spondylodiscitis
from other causes, particularly in view of the differences in microbiological aetiology reported here.
However, including post-surgical cases reflects the reality that the treatment principles are similar
and is consistent with the approach taken in other cases series and the randomised controlled trial by
Bernard et al. [9,10,17].
5. Conclusions
Spondylodiscitis is a rare but serious condition that leads to significant long-term morbidity.
In this study, we have identified several important findings that contribute to our understanding of
this neglected disease. These include the observations that: (a) there is often a substantial interval
between symptom onset and diagnosis; (b) long-term sequelae such as pain are common despite
adequate treatment of infection; and (c) several easily identifiable baseline factors (including duration
of symptoms, diabetes mellitus and neurological involvement at presentation) appear to predict
adverse clinical outcome. Our findings highlight the need for further research, particularly to assess
the impact of interventions to reduce diagnostic delay and to optimise antibiotic and/or surgical
management. Such research has considerable potential to improve the outcome for patients with
spinal infections.
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